Fluorouracil Therapy for Proliferative Vitreoretinopathy after Vitrectomy

https://doi.org/10.1016/0002-9394(83)90452-XGet rights and content

Fluorouracil effectively inhibits epiretinal membrane formation and traction retinal detachment after vitrectomy surgery. When 0.5 mg of fluorouracil was administered intraocularly every 24 hours for seven days, traction retinal detachment two weeks after the intraocular injection of 200,000 cultured retinal pigment epithelial cells occurred in 12 of 12 control eyes but in only six of 14 eyes treated with fluorouracil (P<.001). Four weeks after cell injection, eight of 12 eyes treated with fluorouracil had traction retinal detachments whereas 12 of 12 control eyes did (P<.001). The height of the traction retinal detachment four weeks after intraocular injection of 200,000 cultured retinal pigment epithelial cells was reduced 50% in eyes treated with 0.5 mg of fluorouracil every 24 hours for seven days compared to control eyes (P<.001).

When the number of injected retinal pigment epithelial cells was increased to 400,000 cells and 1.25 mg of fluorouracil was administered intraocularly every 24 hours for seven days, traction retinal detachment two weeks after injection occurred in 15 of 15 eyes in the control group but in none of ten eyes in the treated group. Four weeks after cell injection, eight of eight eyes in the control group and five of five eyes in the fluorouracil-treated group had detachments and the mean height of the detachments in the two groups was equal.

Autoradiography of the epiretinal membranes in eyes injected with 200,000 cultured retinal pigment epithelial cells and labeled for two hours with tritiated thymidine showed that 0.8% of the epiretinal cell nuclei were labeled two weeks after cell injection but that no labeled cells were present in the fluorouracil-treated eyes. Tritiated thymidine labeling of epiretinal cells in the fluorouracil-treated eyes was first noted three weeks after the cell injection. The presence of tritiated thymidine labeling in the fluorouracil-treated eyes correlated with an increase in the number of epiretinal cells and an increase in the incidence of traction retinal detachment.

References (19)

There are more references available in the full text version of this article.

Cited by (85)

  • Proliferative vitreoretinopathy: Prophylactic treatment

    2014, Journal Francais d'Ophtalmologie
  • Gold nanoparticles downregulate VEGF-and IL-1β-induced cell proliferation through Src kinase in retinal pigment epithelial cells

    2010, Experimental Eye Research
    Citation Excerpt :

    Blocking the effects of these two factors (VEGF and IL-1β) may therefore be a potential strategy for treatment of PVR. Recent studies suggest that the pharmacological agents such as 5-fluorouracil (Stern et al., 1983; Blankenship, 1989), daunorubicin (Khawly et al., 1991), retinoids (Araiz et al., 1993), 20-benzoyloxycinnamaldehyde (Lee et al., 2002), alkylphosphocholines (Eibl et al., 2006) are used as effective drugs for the treatment of PVR besides surgery. In the current scenario, several nanoparticles have been suggested as a drug for treatment of various diseases including ocular disorders.

  • Proliferative Vitreoretinopathy

    2005, Retina: Fourth Edition
  • Vitreoretinal Interface

    2005, Retina: Fourth Edition
View all citing articles on Scopus

This study was supported by research grants EY03228 (Dr. Stern), EY02082 (Dr. Anderson), and EY00888 (Dr. Fisher) from the National Eye Institute, Research Career Development Award EY00174 from the National Institutes of Health (Dr. Fisher), and by the Veterans Administration.

Reprint requests to Walter H. Stern, M.D., 4150 Clement St., San Francisco, CA 94121.

View full text